June 17, 2022
1 min watch
Chen Y, et al. Pharmacogenomics — One step nearer to precision medication in headache? A pilot, exploratory examine of the impact of pharmacogenomic phenotypes on the sufficient dosing of Verapamil for migraine prevention. Offered at: American Headache Society annual scientific assembly; June 9-12, 2022; Denver.
Disclosures: Chen stories no related monetary disclosures.
DENVER — Verapamil was proven to be tolerable for migraine prevention at a most dose of 20 mg to 480 mg per day, Yi-Chieh Chen, PharmD, mentioned on the American Headache Society’s annual scientific assembly.
“We discovered a variety of minimally efficient and tolerable verapamil doses in a cohort with varied pharmacogenomic phenotypes,” Chen, of the Mayo Clinic in Rochester, Minnesota, mentioned.